BioSpace News Archive

Dental Restorative Market: Dental Prosthetics to Emerge as Most Promising Product Segment

The global dental restorative market is prognosticated to experience witness a healthy growth curve in the coming years, according to a Transparency Market Research report.

August 19, 2020
·
5 min read
Drug Development

Verona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPDResults expected in the first half of 2021

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the initiation of the second, multiple dose, part of a Phase 2 trial to evaluate the pressurized metered-dose inhaler formulation of ensifentrine in patients with moderate to severe chronic obstructive pulmonary disease.

August 19, 2020
·
8 min read
Dr. Reddy’s Laboratories announces the launch of AVIGAN® (Favipiravir) in India

Dr. Reddy’s Laboratories Ltd. announced the launch of AVIGAN® 200 mg Tablets in India.

August 19, 2020
·
3 min read
Drug Development

Eagle Pharmaceuticals Announces Publication of Preclinical Study of Intranasal Dantrolene in Journal of Alzheimer’s Disease

Eagle Pharmaceuticals, Inc. announced that preclinical research on dantrolene sodium was published today in the peer-reviewed Journal of Alzheimer’s Disease.1 The article reported results from an academic-based study that demonstrated dantrolene sodium administered intranasally improved both memory and cognition in a mouse model of Alzheimer’s disease.

August 19, 2020
·
3 min read
Pharm Country

Kamada and Kedrion Biopharma Announce Results of First and Only U.S. Post-Marketing Pediatric Trial of a Human Rabies Immune Globulin (HRIG); The Study Met Its Primary Objective

The Study of KEDRAB®(Rabies Immune Globulin [Human]) Conducted in Children was the First and Only Pediatric Study for any HRIG Available in U.S.

August 19, 2020
·
9 min read
Drug Development

Pluristem Announces End of Patient Enrollment in its Phase I Hematology StudyTop line efficacy results expected Q1 2021

Pluristem Therapeutics Inc., a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced it has completed patient enrollment in its Phase I study evaluating PLX-R18 as a treatment for incomplete hematopoietic recovery following hematopoietic cell transplantation, in the U.S. and in Israel.

August 19, 2020
·
4 min read
Business

PolyPid Ltd. Provides Corporate Update and Reports Second Quarter 2020 Financial Results

Initiated Phase 3 SHIELD I Trial for D-PLEX100 in Abdominal Surgery and Received Fast Track Designation for D-PLEX100from FDA

August 19, 2020
·
12 min read
Business

Apexigen Appoints Jakob Dupont to Board of Directors

Apexigen, Inc. announced the appointment of Jakob Dupont, M.D., to its Board of Directors.

August 19, 2020
·
2 min read
Drug Development

BioLineRx Achieves Enrollment Target in Phase 3 GENESIS Trial for Planned Interim Analysis

BioLineRx Ltd., a late clinical-stage biopharmaceutical company focused on oncology, announced that a sufficient number of patients have been enrolled in the ongoing GENESIS Phase 3 trial to allow for an interim efficacy analysis to take place in the second half of 2020.

August 19, 2020
·
5 min read
Biotech Beach

National Study Finds Lyme Disease 10 Times Greater Than Reported to CDC; Quidel-Sponsored Webinar Reveals Prevalence and Patterns of Lyme Disease

The number of Americans afflicted with Lyme disease was found to be 10 times greater than the 30,000 cases reported each year to the Centers for Disease Control and Prevention, according to a groundbreaking seven-year clinical study just released.

August 19, 2020
·
3 min read